Ok, let’s just assume for a moment, that the drug does not meet primary endpoint in this AVATAR trial. In the short term, stock will tank to who knows what. Would AVXL recover SOME before Excellence readout in Q4 with impending ALZ readout in Q4 ‘22 or Q1 ‘23? I think question is reasonable given that possibility.
How is everyone hedging profits in this scenario ?
News 
Market Data 
Discover 
